The role of the MDR 1 (p-glycoprotein) gene in multidrug resistance in vitro and in vivo
Identifieur interne : 002B11 ( Istex/Corpus ); précédent : 002B10; suivant : 002B12The role of the MDR 1 (p-glycoprotein) gene in multidrug resistance in vitro and in vivo
Auteurs : Igor B. RoninsonSource :
- Biochemical Pharmacology [ 0006-2952 ] ; 1992.
English descriptors
- KwdEn :
- PCR.
- Teeft :
- Acad, Assay, Biol, Biol chem, Bone marrow, Carcinoma, Carcinoma cells, Cdna, Cell biol, Cell line, Cell lines, Cellular biology, Chemotherapy, Clinical cancer, Coding sequence, Colchicine, Cytotoxic, Cytotoxic selection, Different drugs, Different types, Drug selection, Efflux, Functional role, Gene, Gene family, Gottesman, Gros, Hematopoietic, Hematopoietic progenitor cells, High levels, Highest levels, Human cells, Immunohistochemical, Infectants, Mdr1, Mdr1 expression, Mdr1 gene, Mdr2, Mdrl, Mdrl gene, Multidrug, Multidrug resistance, Multidrug resistance gene, Multidrug resistance gene product, Mutant, Mutant protein, Mutation, Natl, Natl cancer inst, Neoplastic transformation, Normal tissues, Pastan, Pglycoprotein, Pglycoprotein inhibitors, Phenotype, Plenum, Plenum press, Point mutations, Preferential resistance, Proc, Proc natl acad, Roninson, Selective agent, Subpopulation, Tumor cells, Unpublished data, Untreated, Untreated tumors.
Abstract
Abstract: This review describes the studies that address the role of the MDR1 (P-glycoprotein) gene in multidrug resistance in cell lines selected in vitro and in clinical cancer. Molecular genetic studies have demonstrated that expression of P-glycoprotein, an efflux pump acting at diverse lipophilic compounds, is sufficient to provide resistance to a large number of lipophilic drugs in tissue culture. The MDR1 gene is expressed in several normal human tissues associated with secretory or barrier functions and in some bone marrow and blood cells, including hematopoietic progenitor cells. MDR1 expression in clinical cancer is often found in untreated tumors of different types. Several studies showed a correlation between MDR1 expression and tumor resistance to combination chemotherapy. MDR1 expression in untreated tumors may reflect their origin from MDR1-positive normal cells or cellular changes associated with neoplastic transformation or progression. MDR1 expression in some types of cancer may be a marker of a more aggressive subpopulation of tumor cells, possessing multiple mechanisms for resistance to treatment.
Url:
DOI: 10.1016/0006-2952(92)90666-7
Links to Exploration step
ISTEX:C88202C506ADF37D4FCF254C518211F34549042ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The role of the MDR 1 (p-glycoprotein) gene in multidrug resistance in vitro and in vivo</title><author><name sortKey="Roninson, Igor B" sort="Roninson, Igor B" uniqKey="Roninson I" first="Igor B." last="Roninson">Igor B. Roninson</name><affiliation><mods:affiliation>Department of Genetics, University of Illinois at Chicago, Chicago, IL 60612, U.S.A.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C88202C506ADF37D4FCF254C518211F34549042E</idno><date when="1992" year="1992">1992</date><idno type="doi">10.1016/0006-2952(92)90666-7</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-2VPBGDFN-T/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002B11</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002B11</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The role of the MDR 1 (p-glycoprotein) gene in multidrug resistance in vitro and in vivo</title><author><name sortKey="Roninson, Igor B" sort="Roninson, Igor B" uniqKey="Roninson I" first="Igor B." last="Roninson">Igor B. Roninson</name><affiliation><mods:affiliation>Department of Genetics, University of Illinois at Chicago, Chicago, IL 60612, U.S.A.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Biochemical Pharmacology</title><title level="j" type="abbrev">BCP</title><idno type="ISSN">0006-2952</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1992">1992</date><biblScope unit="volume">43</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="95">95</biblScope><biblScope unit="page" to="102">102</biblScope></imprint><idno type="ISSN">0006-2952</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0006-2952</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>PCR</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Acad</term><term>Assay</term><term>Biol</term><term>Biol chem</term><term>Bone marrow</term><term>Carcinoma</term><term>Carcinoma cells</term><term>Cdna</term><term>Cell biol</term><term>Cell line</term><term>Cell lines</term><term>Cellular biology</term><term>Chemotherapy</term><term>Clinical cancer</term><term>Coding sequence</term><term>Colchicine</term><term>Cytotoxic</term><term>Cytotoxic selection</term><term>Different drugs</term><term>Different types</term><term>Drug selection</term><term>Efflux</term><term>Functional role</term><term>Gene</term><term>Gene family</term><term>Gottesman</term><term>Gros</term><term>Hematopoietic</term><term>Hematopoietic progenitor cells</term><term>High levels</term><term>Highest levels</term><term>Human cells</term><term>Immunohistochemical</term><term>Infectants</term><term>Mdr1</term><term>Mdr1 expression</term><term>Mdr1 gene</term><term>Mdr2</term><term>Mdrl</term><term>Mdrl gene</term><term>Multidrug</term><term>Multidrug resistance</term><term>Multidrug resistance gene</term><term>Multidrug resistance gene product</term><term>Mutant</term><term>Mutant protein</term><term>Mutation</term><term>Natl</term><term>Natl cancer inst</term><term>Neoplastic transformation</term><term>Normal tissues</term><term>Pastan</term><term>Pglycoprotein</term><term>Pglycoprotein inhibitors</term><term>Phenotype</term><term>Plenum</term><term>Plenum press</term><term>Point mutations</term><term>Preferential resistance</term><term>Proc</term><term>Proc natl acad</term><term>Roninson</term><term>Selective agent</term><term>Subpopulation</term><term>Tumor cells</term><term>Unpublished data</term><term>Untreated</term><term>Untreated tumors</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: This review describes the studies that address the role of the MDR1 (P-glycoprotein) gene in multidrug resistance in cell lines selected in vitro and in clinical cancer. Molecular genetic studies have demonstrated that expression of P-glycoprotein, an efflux pump acting at diverse lipophilic compounds, is sufficient to provide resistance to a large number of lipophilic drugs in tissue culture. The MDR1 gene is expressed in several normal human tissues associated with secretory or barrier functions and in some bone marrow and blood cells, including hematopoietic progenitor cells. MDR1 expression in clinical cancer is often found in untreated tumors of different types. Several studies showed a correlation between MDR1 expression and tumor resistance to combination chemotherapy. MDR1 expression in untreated tumors may reflect their origin from MDR1-positive normal cells or cellular changes associated with neoplastic transformation or progression. MDR1 expression in some types of cancer may be a marker of a more aggressive subpopulation of tumor cells, possessing multiple mechanisms for resistance to treatment.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>mdr1</json:string><json:string>multidrug</json:string><json:string>multidrug resistance</json:string><json:string>roninson</json:string><json:string>mdr1 expression</json:string><json:string>pglycoprotein</json:string><json:string>mdr1 gene</json:string><json:string>gottesman</json:string><json:string>pastan</json:string><json:string>efflux</json:string><json:string>tumor cells</json:string><json:string>natl</json:string><json:string>chemotherapy</json:string><json:string>cytotoxic</json:string><json:string>mutation</json:string><json:string>colchicine</json:string><json:string>biol</json:string><json:string>cdna</json:string><json:string>hematopoietic</json:string><json:string>mdrl</json:string><json:string>mdr2</json:string><json:string>cell lines</json:string><json:string>gros</json:string><json:string>phenotype</json:string><json:string>proc</json:string><json:string>acad</json:string><json:string>mutant</json:string><json:string>infectants</json:string><json:string>subpopulation</json:string><json:string>plenum press</json:string><json:string>plenum</json:string><json:string>proc natl acad</json:string><json:string>cellular biology</json:string><json:string>immunohistochemical</json:string><json:string>cell biol</json:string><json:string>clinical cancer</json:string><json:string>carcinoma</json:string><json:string>multidrug resistance gene</json:string><json:string>preferential resistance</json:string><json:string>untreated tumors</json:string><json:string>gene</json:string><json:string>functional role</json:string><json:string>normal tissues</json:string><json:string>gene family</json:string><json:string>cytotoxic selection</json:string><json:string>bone marrow</json:string><json:string>mdrl gene</json:string><json:string>biol chem</json:string><json:string>different types</json:string><json:string>assay</json:string><json:string>untreated</json:string><json:string>coding sequence</json:string><json:string>unpublished data</json:string><json:string>natl cancer inst</json:string><json:string>point mutations</json:string><json:string>carcinoma cells</json:string><json:string>cell line</json:string><json:string>different drugs</json:string><json:string>mutant protein</json:string><json:string>selective agent</json:string><json:string>human cells</json:string><json:string>drug selection</json:string><json:string>highest levels</json:string><json:string>neoplastic transformation</json:string><json:string>pglycoprotein inhibitors</json:string><json:string>hematopoietic progenitor cells</json:string><json:string>multidrug resistance gene product</json:string><json:string>high levels</json:string></teeft></keywords><subject><json:item><lang><json:string>eng</json:string></lang><value>PCR : polymerase chain reaction</value></json:item></subject><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><qualityIndicators><score>8.968</score><pdfWordCount>5901</pdfWordCount><pdfCharCount>37906</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>8</pdfPageCount><pdfPageSize>540 x 778 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>164</abstractWordCount><abstractCharCount>1134</abstractCharCount><keywordCount>1</keywordCount></qualityIndicators><title>The role of the MDR 1 (p-glycoprotein) gene in multidrug resistance in vitro and in vivo</title><pii><json:string>0006-2952(92)90666-7</json:string></pii><genre><json:string>research-article</json:string></genre><host><title>Biochemical Pharmacology</title><language><json:string>unknown</json:string></language><publicationDate>1992</publicationDate><issn><json:string>0006-2952</json:string></issn><pii><json:string>S0006-2952(00)X0844-1</json:string></pii><volume>43</volume><issue>1</issue><pages><first>95</first><last>102</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1992</json:string><json:string>1280</json:string></date><geogName></geogName><orgName><json:string>American Cancer Society</json:string><json:string>National Cancer Institute</json:string><json:string>University of Illinois</json:string><json:string>Faculty Research Award</json:string><json:string>Department of Genetics</json:string><json:string>Bristol-Myers-Squibb Co</json:string></orgName><orgName_funder><json:string>Bristol-Myers-Squibb Co</json:string></orgName_funder><orgName_provider></orgName_provider><persName><json:string>R. S. Weinstein</json:string><json:string>M. M. Gottesman</json:string><json:string>J. S. Coon</json:string><json:string>D. D. von Hoff</json:string><json:string>M. Kriegler</json:string><json:string>I. Pastan</json:string><json:string>T. A. Holzmayer</json:string><json:string>U.S.A. Tel</json:string><json:string>T. Tsuruo</json:string><json:string>A. Sara</json:string><json:string>C. Zelnick</json:string><json:string>B. Morse</json:string></persName><placeName><json:string>IL</json:string><json:string>Chicago</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>[50]</json:string><json:string>[4]</json:string><json:string>[58-61,64]</json:string><json:string>Guild et al. [22]</json:string><json:string>Neyfakh et al. [43]</json:string><json:string>[18]</json:string><json:string>[55]</json:string><json:string>[8]</json:string><json:string>[39]</json:string><json:string>[1]</json:string><json:string>[65]</json:string><json:string>List et al. [53]</json:string><json:string>[49]</json:string><json:string>[3]</json:string><json:string>[64]</json:string><json:string>[37]</json:string><json:string>[56,57]</json:string><json:string>[48, 52]</json:string><json:string>[7]</json:string><json:string>[36]</json:string><json:string>[47-49]</json:string><json:string>[9]</json:string><json:string>[51]</json:string><json:string>[58-61]</json:string><json:string>[38, 39]</json:string><json:string>[2]</json:string><json:string>[46]</json:string><json:string>[62, 63]</json:string><json:string>[19]</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-2VPBGDFN-T</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - pharmacology & pharmacy</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - pharmacology & pharmacy</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Pharmacology, Toxicology and Pharmaceutics</json:string><json:string>3 - Pharmacology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - Biochemistry</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>1992</publicationDate><author><json:item><name>Igor B. Roninson</name><affiliations><json:string>Department of Genetics, University of Illinois at Chicago, Chicago, IL 60612, U.S.A.</json:string></affiliations></json:item></author><articleId><json:string>92906667</json:string></articleId><arkIstex>ark:/67375/6H6-2VPBGDFN-T</arkIstex><abstract>Abstract: This review describes the studies that address the role of the MDR1 (P-glycoprotein) gene in multidrug resistance in cell lines selected in vitro and in clinical cancer. Molecular genetic studies have demonstrated that expression of P-glycoprotein, an efflux pump acting at diverse lipophilic compounds, is sufficient to provide resistance to a large number of lipophilic drugs in tissue culture. The MDR1 gene is expressed in several normal human tissues associated with secretory or barrier functions and in some bone marrow and blood cells, including hematopoietic progenitor cells. MDR1 expression in clinical cancer is often found in untreated tumors of different types. Several studies showed a correlation between MDR1 expression and tumor resistance to combination chemotherapy. MDR1 expression in untreated tumors may reflect their origin from MDR1-positive normal cells or cellular changes associated with neoplastic transformation or progression. MDR1 expression in some types of cancer may be a marker of a more aggressive subpopulation of tumor cells, possessing multiple mechanisms for resistance to treatment.</abstract><pmid><json:string>1346497</json:string></pmid><serie><title>Proc Natl Acad Sci USA</title><language><json:string>unknown</json:string></language><volume>83</volume><pages><first>337</first><last>341</last></pages></serie><copyrightDate>1992</copyrightDate><doi><json:string>10.1016/0006-2952(92)90666-7</json:string></doi><id>C88202C506ADF37D4FCF254C518211F34549042E</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-2VPBGDFN-T/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-2VPBGDFN-T/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-2VPBGDFN-T/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">The role of the MDR 1 (p-glycoprotein) gene in multidrug resistance in vitro and in vivo</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>elsevier</p></licence></availability><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M"></p><date>1992</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">The role of the MDR 1 (p-glycoprotein) gene in multidrug resistance in vitro and in vivo</title><author xml:id="author-0000"><persName><forename type="first">Igor B.</forename><surname>Roninson</surname></persName><note type="correspondence"><p>Correspondence address: Department of Genetics (M/C 669), University of Illinois at Chicago, 808 South Wood St, Chicago, IL 60612, U.S.A. Tel. (312) 996-3486; FAX (312) 413-0353.</p></note><affiliation>Department of Genetics, University of Illinois at Chicago, Chicago, IL 60612, U.S.A.</affiliation></author><idno type="istex">C88202C506ADF37D4FCF254C518211F34549042E</idno><idno type="ark">ark:/67375/6H6-2VPBGDFN-T</idno><idno type="DOI">10.1016/0006-2952(92)90666-7</idno><idno type="PII">0006-2952(92)90666-7</idno><idno type="article-id">92906667</idno></analytic><monogr><title level="j">Biochemical Pharmacology</title><title level="j" type="abbrev">BCP</title><idno type="pISSN">0006-2952</idno><idno type="PII">S0006-2952(00)X0844-1</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1992"></date><biblScope unit="volume">43</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="95">95</biblScope><biblScope unit="page" to="102">102</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1992</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: This review describes the studies that address the role of the MDR1 (P-glycoprotein) gene in multidrug resistance in cell lines selected in vitro and in clinical cancer. Molecular genetic studies have demonstrated that expression of P-glycoprotein, an efflux pump acting at diverse lipophilic compounds, is sufficient to provide resistance to a large number of lipophilic drugs in tissue culture. The MDR1 gene is expressed in several normal human tissues associated with secretory or barrier functions and in some bone marrow and blood cells, including hematopoietic progenitor cells. MDR1 expression in clinical cancer is often found in untreated tumors of different types. Several studies showed a correlation between MDR1 expression and tumor resistance to combination chemotherapy. MDR1 expression in untreated tumors may reflect their origin from MDR1-positive normal cells or cellular changes associated with neoplastic transformation or progression. MDR1 expression in some types of cancer may be a marker of a more aggressive subpopulation of tumor cells, possessing multiple mechanisms for resistance to treatment.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Abbreviations</head><item><term>PCR</term><term>polymerase chain reaction</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1992">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-2VPBGDFN-T/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla" xml:lang="en"><item-info><jid>BCP</jid><aid>92906667</aid><ce:pii>0006-2952(92)90666-7</ce:pii><ce:doi>10.1016/0006-2952(92)90666-7</ce:doi><ce:copyright type="unknown" year="1992"></ce:copyright></item-info><head><ce:title>The role of the <ce:italic>MDR</ce:italic>1 (p-glycoprotein) gene in multidrug resistance <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic></ce:title><ce:author-group><ce:author><ce:given-name>Igor B.</ce:given-name><ce:surname>Roninson</ce:surname><ce:cross-ref refid="COR1"><ce:sup loc="post">∗</ce:sup></ce:cross-ref></ce:author><ce:affiliation><ce:textfn>Department of Genetics, University of Illinois at Chicago, Chicago, IL 60612, U.S.A.</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text>Correspondence address: Department of Genetics (M/C 669), University of Illinois at Chicago, 808 South Wood St, Chicago, IL 60612, U.S.A. Tel. (312) 996-3486; FAX (312) 413-0353.</ce:text></ce:correspondence></ce:author-group><ce:abstract class="author"><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para view="all" id="simple-para.0010">This review describes the studies that address the role of the <ce:italic>MDR</ce:italic>1 (P-glycoprotein) gene in multidrug resistance in cell lines selected <ce:italic>in vitro</ce:italic> and in clinical cancer. Molecular genetic studies have demonstrated that expression of P-glycoprotein, an efflux pump acting at diverse lipophilic compounds, is sufficient to provide resistance to a large number of lipophilic drugs in tissue culture. The <ce:italic>MDR</ce:italic>1 gene is expressed in several normal human tissues associated with secretory or barrier functions and in some bone marrow and blood cells, including hematopoietic progenitor cells. <ce:italic>MDR</ce:italic>1 expression in clinical cancer is often found in untreated tumors of different types. Several studies showed a correlation between <ce:italic>MDR</ce:italic>1 expression and tumor resistance to combination chemotherapy. <ce:italic>MDR</ce:italic>1 expression in untreated tumors may reflect their origin from <ce:italic>MDR</ce:italic>1-positive normal cells or cellular changes associated with neoplastic transformation or progression. <ce:italic>MDR</ce:italic>1 expression in some types of cancer may be a marker of a more aggressive subpopulation of tumor cells, possessing multiple mechanisms for resistance to treatment.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords class="abr"><ce:section-title>Abbreviations</ce:section-title><ce:keyword><ce:text>PCR</ce:text><ce:keyword><ce:text>polymerase chain reaction</ce:text></ce:keyword></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>The role of the MDR 1 (p-glycoprotein) gene in multidrug resistance in vitro and in vivo</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>The role of the</title></titleInfo><name type="personal"><namePart type="given">Igor B.</namePart><namePart type="family">Roninson</namePart><affiliation>Department of Genetics, University of Illinois at Chicago, Chicago, IL 60612, U.S.A.</affiliation><description>Correspondence address: Department of Genetics (M/C 669), University of Illinois at Chicago, 808 South Wood St, Chicago, IL 60612, U.S.A. Tel. (312) 996-3486; FAX (312) 413-0353.</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1992</dateIssued><copyrightDate encoding="w3cdtf">1992</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: This review describes the studies that address the role of the MDR1 (P-glycoprotein) gene in multidrug resistance in cell lines selected in vitro and in clinical cancer. Molecular genetic studies have demonstrated that expression of P-glycoprotein, an efflux pump acting at diverse lipophilic compounds, is sufficient to provide resistance to a large number of lipophilic drugs in tissue culture. The MDR1 gene is expressed in several normal human tissues associated with secretory or barrier functions and in some bone marrow and blood cells, including hematopoietic progenitor cells. MDR1 expression in clinical cancer is often found in untreated tumors of different types. Several studies showed a correlation between MDR1 expression and tumor resistance to combination chemotherapy. MDR1 expression in untreated tumors may reflect their origin from MDR1-positive normal cells or cellular changes associated with neoplastic transformation or progression. MDR1 expression in some types of cancer may be a marker of a more aggressive subpopulation of tumor cells, possessing multiple mechanisms for resistance to treatment.</abstract><subject lang="en"><genre>Abbreviations</genre><topic>PCR : polymerase chain reaction</topic></subject><relatedItem type="host"><titleInfo><title>Biochemical Pharmacology</title></titleInfo><titleInfo type="abbreviated"><title>BCP</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1992</dateIssued></originInfo><identifier type="ISSN">0006-2952</identifier><identifier type="PII">S0006-2952(00)X0844-1</identifier><part><date>1992</date><detail type="volume"><number>43</number><caption>vol.</caption></detail><detail type="issue"><number>1</number><caption>no.</caption></detail><extent unit="issue-pages"><start>1</start><end>117</end></extent><extent unit="pages"><start>95</start><end>102</end></extent></part></relatedItem><identifier type="istex">C88202C506ADF37D4FCF254C518211F34549042E</identifier><identifier type="ark">ark:/67375/6H6-2VPBGDFN-T</identifier><identifier type="DOI">10.1016/0006-2952(92)90666-7</identifier><identifier type="PII">0006-2952(92)90666-7</identifier><identifier type="ArticleID">92906667</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-2VPBGDFN-T/record.json</uri></json:item></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B11 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002B11 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:C88202C506ADF37D4FCF254C518211F34549042E
|texte= The role of the MDR 1 (p-glycoprotein) gene in multidrug resistance in vitro and in vivo
}}
| This area was generated with Dilib version V0.6.33. |  |